ArticleActa obstetricia et gynecologica Scandinavica2026
Real-world evaluation of a population-based vaginal self-sampling program for cervical cancer prevention in Region Skåne, Sweden.
Article in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionCervical cancer represents a significant public health challenge worldwide. To improve screening accessibility and participation, we implemented vaginal human papilloma virus (HPV) self-sampling as part of an organized cervical cancer prevention strategy. This study aimed to evaluate the implementation and outcomes of the self-sampling program in a real-world setting. MATERIAL AND
methodsBetween September 1, 2021 and December 31, 2024, a total of 557 976 vaginal self-sampling kits were distributed. Follow-up with cervical sampling continued through April 2025. Data were collected using the Laboratory Information Management System (LIMS) and the Melior Journal system.
resultsOf the distributed kits, 208 386 were returned, yielding an adherence rate of 37% (208 386/557 976). Among the valid samples, 19% (39 697/204 763) tested positive for HPV. Follow-up adherence among HPV-positive women was 81% (32 305/39 697), defined as attendance at follow-up clinics by the end of the fourth subsequent calendar month. Cervical samples were HPV-positive in 39% (12 495/32 305) and HPV16 or HPV18/45 were detected in 2157 cases (17%). Cytological analysis identified high-grade cervical dysplasia in 759 women (6.1%, 759/12 505) and histopathology confirmed its presence in 980 cases (13%, 980/7641). Cervical cancer was diagnosed in 32 cervical biopsies (0.4%, 32/7647).
conclusionsThe vaginal self-sampling program was effective in detecting HPV. Its capacity to identify HPV types and significant cytological abnormalities underscores its potential for facilitating early detection, enhancing screening coverage and timely clinical intervention, thereby reducing the incidence of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.